NR1H4 and primary biliary cholangitis: Abnormally high levels of BAs are one of the pathogenic factors contributing to cholestatic liver diseases, and FXR regulates the levels of hepatic BAs, thus being viewed as a therapeutic target for primary biliary cholangitis [49, 50].